Share this page!

EnvisionRheumat Profile picture
Twitter logo
Jun 3 • 4 tweets • 4 min read
#EULAR2022
Apples AND/OR oranges? Differentiating common and uncommon arthritides
Enthesitis can be seen in Upto 40% patients with PsA
Enthesitis is associated with
♦️⬆️Disease activity
♦️Synovitis & dactylitis
♦️⬆️Radiographic Damage
♦️ Poor functional Status ImageImageImage
#EULAR2022
Apples AND/OR oranges? Differentiating common and uncommon arthritides
♦️Fibromyalgia can be seen in 25% of PsA pts
♦️ Asso with
♦️ ⬆️ Disease activity
♦️ Poor Response to Rx 👉🏻 Change of Rx ImageImageImage
#EULAR2022
Apples AND/OR oranges? Differentiating common and uncommon arthritides
♦️ It is very difficult to differentiate Enthesitis from FMS tender points
♦️ they seem to be mutually exclusive 👉🏻 ⬆️ enthesitis in pts without FMS
♦️ USG is the modality of Choice ImageImageImageImage
#EULAR2022
Apples AND/OR oranges? Differentiating common and uncommon arthritides Image

• • •

Missing some Tweet in this thread? You can try to force a refresh
　

Keep Current with EnvisionRheumat

EnvisionRheumat Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ERheumat

EnvisionRheumat Profile picture
Jun 6
#EULAR2022
Pain in rheumatic and musculoskeletal diseases
😩Pathophysiology of pain in patients with RMDs is not always Nociceptive and can be nociplastic
😩Differentiation between inflammation-related and unrelated pain is important Image
#EULAR2022
Pain in rheumatic and musculoskeletal diseases
😩Pain can be Nociceptive, Neuropathic and Nociplastic
😩Or can be primary/Secondary
😩Pain sensitisation, processing and response are important for proper assimilation of pain ImageImageImageImage
#EULAR2022
😩No standard method to measure central pain
😩FMS can be present in upto 50% of patients
😩Asso with Higher disease activity and higher biologic use/change
😩A no. of central mechanisms contribute to pain ImageImageImageImage
Read 7 tweets
EnvisionRheumat Profile picture
Jun 5
#EULAR2022
What is New (WIN)
Osteoarthritis – evolving treatments
This talk is a must-watch on-demand - highly recommended
🗝Proposed NICE-UK guidelines for Image
#EULAR2022
🗝Most trials have tried correcting catabolic pathway
🗝 Most trials in OA have failed
🗝Cartilage though sparsely cellular/vascular exquisitely sensitive to injury
🗝 Max polymorphism in OA is found in the Anabolic pathway ImageImageImageImage
#EULAR2022
What is New (WIN)
Osteoarthritis – evolving treatments
🗝Shear stress leads to damage while compression leads to regeneration
🗝Has been utilized in Joint distraction showing good results Image
Read 6 tweets
EnvisionRheumat Profile picture
Jun 4
#EULAR2022
Rheumatology across boundaries
The eye in rheumatic diseases
🧿The Pathophysiology of Uveitis is poorly understood
🧿 Uveitis is thought to be due to enthesitis of ciliary body attachment
🧿TH17 and TH1 are major mediators of inflammation ImageImageImageImage
#EULAR2022
Rheumatology across boundaries
The eye in rheumatic diseases
🧿 Most common extra-articular feature
🧿 HLA-B27+vity, Recurrent uveitis and IBP 🚩 for rheumatology referral ImageImageImage
#EULAR2022
Rheumatology across boundaries
The eye in rheumatic diseases
🧿 Non-Anterior non infectious Uveitis has a no of causes 👉🏻 makes studying the disease difficult
🧿 Sarcoid, Behcet's other imp causes
🧿 Topical Rx 1st for Anterior Uveitis
🧿 Systemic 1st for NIU ImageImageImage
Read 6 tweets
EnvisionRheumat Profile picture
Jun 4
#EULAR2022
How To Treat (HOT)
Anti-phospholipid syndrome Image
#EULAR2022
How To Treat (HOT)
Anti-phospholipid syndrome
🩸Primary Thromboprophylaxis
🩸Aspirin is recommended but might not be sufficient
🩸VKA use is asso. ⬆️ Bleeding risk (Risk>Benefit) ImageImageImageImage
#EULAR2022
How To Treat (HOT)
Anti-phospholipid syndrome
🩸Secondary Prophylaxis
🩸INR: 2-3 for venous thrombosis (Controversial)
🩸Is not effective in preventing arterial events though ImageImageImageImage
Read 7 tweets
EnvisionRheumat Profile picture
Jun 4
#EULAR2022
IBD management for Rheumatologist
🔎The options have been increasing over the years
🔎Remission rates have still not crossed 30-40% Ballpark ImageImageImage
#EULAR2022
IBD management for Rheumatologist
🔎Target of therapy is
♦️Clinical remission in short term
♦️Histological remission in medium-term
♦️Disease Modification in Long
🔎Histological activity better marker of future Flare ImageImageImage
#EULAR2022
IBD management for Rheumatologist
🔎Very Few Head to head trial to decide biologic of choice
🔎 Vedoli>Adali but Ustki=Adali ImageImageImage
Read 7 tweets
EnvisionRheumat Profile picture
Jun 4
#EULAR2022
New treatment strategies and approaches to young adults with inflammatory myositis
Treatment options available their doses in IIM Image
#EULAR2022
New treatment strategies and approaches to young adults with inflammatory myositis
♦️MTX+GC>>MTX+CIC>GC alone ImageImage
#EULAR2022
New treatment strategies and approaches to young adults with inflammatory myositis
🪩RIM trial
♦️Better response in JDM
♦️Antibody positive (Mi2,Jo1 +ve ) performed better than Ab negetive ImageImage
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!

:(